Prognosis
AstraZeneca to Hasten Trial Update After U.S. Calls Results Outdated
- Independent monitoring board expressed concerns over data
- Astra said on Monday shot was 79% effective in U.S. trial
This article is for subscribers only.
AstraZeneca Plc plans to release up-to-date results from the U.S. study of its Covid-19 vaccine within 48 hours following criticism from a science agency that an analysis published Monday included old information.
The U.K. drugmaker will “immediately engage” with the independent panel monitoring the trial to share the latest efficacy information, AstraZeneca said Tuesday. The earlier results were based on data gathered through Feb. 17.